Α. Kotsakis

500 citations

23 papers · 338 indexed · h-index 11

Impact in

Oncology
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
Otorhinolaryngology top 10%

Papers in ⓘ

Oncology 19
- Lung Cancer Research Studies 9
- Cancer Treatment and Pharmacology 4
- Peptidase Inhibition and Analysis 3
Pulmonary and Respiratory Medicine 15
- Lung Cancer Treatments and Mutations 13
- Lung Cancer Diagnosis and Treatment 5

Co-authors: Vassilis Georgoulias (6 shared papers)Athanassios Argiris (8 shared papers)Athanasios Galanis (1 shared paper)Dimitris Mavroudis (1 shared paper)Despoina Aggouraki (3 shared papers)Paul Cordopatis (1 shared paper)Kostas Kosmatopoulos (1 shared paper)Sofia Agelaki (4 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Lung Cancer (6 papers)Cancer Chemotherapy and Pharmacology (2 papers)Annals of Oncology (2 papers)Clinical Epigenetics (1 paper)
Partner nations: Greece United States Australia

In The Last Decade

Α. Kotsakis

22 papers receiving 331 citations

Peers

Countries citing papers authored by Α. Kotsakis

Since Specialization

Citations

This map shows the geographic impact of Α. Kotsakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Α. Kotsakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Α. Kotsakis more than expected).

Fields of papers citing papers by Α. Kotsakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Α. Kotsakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Α. Kotsakis. The network helps show where Α. Kotsakis may publish in the future.

Co-authors

The 25 scholars most cited alongside Α. Kotsakis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Α. Kotsakis Line = papers co-authored together Α. Kotsakis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide Journal of Clinical Oncology ·I. Bolonaki, Α. Kotsakis, Elsa Papadimitraki, Despoina Aggouraki, G. Konsolakis, Aphrodite Vagia, Charalambos Christophylakis, Irini Nikoloudi, Elefterios Magganas, Athanasios Galanis, Paul Cordopatis, Kostas Kosmatopoulos, Vassilis Georgoulias, Dimitris Mavroudis	2007	85
2	Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. Journal of Clinical Oncology ·L. Vamvakas, Sofia Agelaki, Ν. Kentepozidis, Athanasios Karampeazis, Athanasios Pallis, C. Christophyllakis, Α. Kotsakis, Ioannis Boukovinas, D. Mavroudis, V. Georgoulias	2010	35
3	Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group Lung Cancer ·Giannis Mountzios, Christos Emmanouilidis, N. Vardakis, Emmanouil Kontopodis, Dora Hatzidaki, Evagelos Popis, Niki Karachaliou, Α. Kotsakis, M. Agelidou, Vassilis Georgoulias	2012	33
4	DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection Clinical Epigenetics ·Athina Markou, Dora Londra, Victoria Tserpeli, J. G. Kollias, Emilia Tsaroucha, Ioannis Vamvakaris, Κonstantinos Potaris, Ioannis S. Pateras, Α. Kotsakis, Vassilis Georgoulias, Evi Lianidou	2022	29
5	3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial European Journal of Cancer ·R. Stahel, Urania Dafni, Oliver Gautschi, Enriqueta Felip, Alessandra Curioni‐Fontecedro, Solange Peters, Bartomeu Massutí, F. Cardenal, S. Ponce Aix, Martin Früh, Miklos Pless, Sanjay Popat, Α. Kotsakis, Sinéad Cuffe, Paolo Bidoli, Adolfo Favaretto, Enric Carcereny, M. Sánchez Ronco, M.A. Molina, R. Rosell	2015	24
6	Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) Cancer Chemotherapy and Pharmacology ·Panagiotis Katsaounis, Α. Kotsakis, Sofia Agelaki, E. Kontopodis, Athina Agelidou, Nikolaos Kentepozidis, L. Vamvakas, Athina Christopoulou, Niki Karachaliou, Dora Hatzidaki, Vassilis Georgoulias	2015	18
7	A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer Lung Cancer ·Suresh S. Ramalingam, Α. Kotsakis, Ahmad A. Tarhini, Dwight E. Heron, Rebecca L. Smith, David Friedland, Daniel P. Petro, L. E. Raez, Julie R. Brahmer, Joel S. Greenberger, (unknown), Pamela A. Hershberger, Rodney J. Landreneau, James D. Luketich, Chandra P. Belani, Athanassios Argiris	2013	17
8	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer Annals of Oncology ·Athanassios Argiris, M. V. Karamouzis, Ryan P. Smith, Α. Kotsakis, Michael K. Gibson, Stephen Y. Lai, S. Kim, Barton F. Branstetter, Y. Shuai, Marjorie Romkes, Ling Wang, Jennifer R. Grandis, Robert L. Ferris, Jonas T. Johnson, Dwight E. Heron	2011	12
9	Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report Journal of Clinical Oncology ·Michael K. Gibson, M.S. Kies, Sohyoung Kim, P. Savvides, Α. Kotsakis, G. R. Blumenschein, Frank Worden, H. Chen, Jennifer R. Grandis, Athanassios Argiris	2009	12
10	Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC) Journal of Clinical Oncology ·Α. Kotsakis, Ahmad A. Tarhini, Daniel P. Petro, R. Flaugh, Geetha D. Vallabhaneni, Chandra P. Belani, D. Friedland, Athanassios Argiris	2009	11
11	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update Expert Review of Respiratory Medicine ·Alexios Matikas, Vassilis Georgoulias, Α. Kotsakis	2016	10
12	Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. Journal of Clinical Oncology ·Athanassios Argiris, Α. Kotsakis, S. Kim, F. P. Worden, P. Savvides, Michael K. Gibson, G. R. Blumenschein, H. X. Chen, Jennifer R. Grandis, M.S. Kies	2011	10
13	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome Clinical Breast Cancer ·Vassiliki Kotoula, Kalliopi Tsakiri, Georgia-Angeliki Koliou, Georgios Lazaridis, Kyriaki Papadopoulou, Eleni Giannoulatou, Ioannis Tikas, Christos Christodoulou, Kyriakos Chatzopoulos, Mattheos Bobos, George Pentheroudakis, Eleftheria Tsolaki, Anna Batistatou, Α. Kotsakis, Αngelos Koutras, Helena Linardou, Evangelia Razis, Eleni Res, Dimitrios Pectasides, George Fountzilas	2018	8
14	Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer Cancer Chemotherapy and Pharmacology ·Vasilis Georgoulias, Stella Apostolaki, V. Bozionelou, Eleni Politaki, Maria Perraki, Nefeli Georgoulia, Kostas Kalbakis, Α. Kotsakis, Alexandros Xyrafas, Sofia Agelaki, D. Mavroudis	2014	7
15	Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Α. Kotsakis, Suresh S. Ramalingam, Ahmad A. Tarhini, Dwight E. Heron, R. Stephen Smith, David Friedland, Daniel P. Petro, L. E. Raez, Julie R. Brahmer, Joel S. Greenberger, (unknown), Pamela A. Hershberger, Rodney J. Landreneau, Chandra P. Belani, James D. Luketich, Athanassios Argiris	2011	7
16	Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial Lung Cancer ·Vassilis Georgoulias, Ch Kourousis, N. Androulakis, S. Kakolyris, Meletios Α. Dimopoulos, E. Papadakis, Demosthenes Bouros, F Apostolopoulou, C Papadimitriou, Athina Agelidou, V Tzianni, F Apostolaki, Kostas Hatzakis, K. Kalbakis, Α. Kotsakis, E. Sarra, N. Vardakis, J. Vlachonicolis	1998	5
17	A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology ·Robert L. Ferris, Α. Kotsakis, Dwight E. Heron, S. Kim, Umamaheswar Duvvuri, G.J. Kubicek, Jennifer R. Grandis, Jonas T. Johnson, Athanassios Argiris	2010	4
18	Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxelbased chemotherapy: a multicenter phase II study Lung Cancer ·N. Androulakis, Ch Kourousis, S. Kakolyris, S. Tzannes, E. Papadakis, C Papadimitriou, A Geroyanni, Theodora-Isavella Georgopoulou, Ioanna Dimopoulou, J Souklakos, V Tzianni, F Apostolaki, Α. Kotsakis, N. Vardakis, T Kalikaki, Dora Hatzidaki, V. Georgoulias	1998	3
19	Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC) Lung Cancer ·S. Kakolyris, Charalambos Kouroussis, John Souglakos, N. Androulakis, D. Mavroudis, Kostas Kalbakis, Α. Kotsakis, E. Sara, Sofia Agelaki, George Prinianakis, N. Vardakis, George Samonis, V. Georgoulias	1998	2
20	Clinical efficacy and immunogenicity of the optimized cryptic peptide TERT_572Y vaccine (Vx-001) in patients with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology ·K. Kosmatopoulos, E. Bolonaki, Despoina Aggouraki, E. Nikoloudi, Peggy Kanellou, E. Papadimitraki, Α. Kotsakis, D. Mavroudis, V. Georgoulias	2006	2

About Α. Kotsakis

Α. Kotsakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Otorhinolaryngology and Immunology, having authored 23 papers that have together received 338 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (9 papers), Lung Cancer Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (4 papers), Head and Neck Cancer Studies (4 papers), Cancer therapeutics and mechanisms (3 papers), Immunotherapy and Immune Responses (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Oncology (223 citations), Otorhinolaryngology (29 citations), Pulmonary and Respiratory Medicine (147 citations), Cancer Research (53 citations) and Biotechnology (30 citations). Α. Kotsakis has collaborated with scholars based in Greece, United States and Australia. Frequent co-authors include Vassilis Georgoulias, Athanassios Argiris, Athanasios Galanis, Dimitris Mavroudis, Despoina Aggouraki, Paul Cordopatis, Kostas Kosmatopoulos, Sofia Agelaki, L. Vamvakas and Niki Karachaliou. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Cancer Chemotherapy and Pharmacology, Annals of Oncology and Clinical Epigenetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact